200 related articles for article (PubMed ID: 28848170)
1. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
4. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
[TBL] [Abstract][Full Text] [Related]
5. [Motivational interviewing for cannabis users with psychotic disorders].
Bonsack C; Montagrin Y; Favrod J; Gibellini S; Conus P
Encephale; 2007 Oct; 33(5):819-26. PubMed ID: 18357854
[TBL] [Abstract][Full Text] [Related]
6. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
7. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
[TBL] [Abstract][Full Text] [Related]
8. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
Katz G; Kunyvsky Y; Hornik-Lurie T; Raskin S; Abramowitz MZ
Isr J Psychiatry Relat Sci; 2016; 53(3):10-15. PubMed ID: 28492376
[TBL] [Abstract][Full Text] [Related]
9. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
Winstock A; Lynskey M; Borschmann R; Waldron J
J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
[TBL] [Abstract][Full Text] [Related]
10. Psychosis and synthetic cannabinoids.
Deng H; Verrico CD; Kosten TR; Nielsen DA
Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
Every-Palmer S
Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
[TBL] [Abstract][Full Text] [Related]
12. New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.
Alhassan A; Prahad SR; Burk BG; Fargason RE; Birur B
Psychopharmacol Bull; 2024 Mar; 54(1):33-39. PubMed ID: 38449474
[TBL] [Abstract][Full Text] [Related]
13. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
14. Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users.
Deng H; Desai PV; Mohite S; Okusaga OO; Zhang XY; Nielsen DA; Kosten TR
J Stud Alcohol Drugs; 2019 Mar; 80(2):230-235. PubMed ID: 31014468
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids and psychosis.
Sewell RA; Ranganathan M; D'Souza DC
Int Rev Psychiatry; 2009 Apr; 21(2):152-62. PubMed ID: 19367509
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
Tait RJ; Caldicott D; Mountain D; Hill SL; Lenton S
Clin Toxicol (Phila); 2016; 54(1):1-13. PubMed ID: 26567470
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids and Psychosis.
D'Souza DC; Radhakrishnan R; Sherif M; Cortes-Briones J; Cahill J; Gupta S; Skosnik PD; Ranganathan M
Curr Pharm Des; 2016; 22(42):6380-6391. PubMed ID: 27568729
[TBL] [Abstract][Full Text] [Related]
18. Cannabis, cannabinoids, and health.
Lafaye G; Karila L; Blecha L; Benyamina A
Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
[TBL] [Abstract][Full Text] [Related]
19. Synthetic cannabinoid use: recognition and management.
Castellanos D; Thornton G
J Psychiatr Pract; 2012 Mar; 18(2):86-93. PubMed ID: 22418399
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Predictors of Synthetic Cannabinoid Use in Adolescents.
Ninnemann AL; Jeong Choi H; Stuart GL; Temple JR
Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
